{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:26Z","timestamp":1771884566862,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jhep.2016.02.042","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T19:07:34Z","timestamp":1457204854000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial"],"prefix":"10.1016","volume":"65","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hezode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.02.042_b0005","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2016.02.042_b0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","article-title":"Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.042_b0020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.042_b0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jamainternmed.2014.2903","article-title":"The portrait of an adult liver transplant recipient in the United States from 1987 to 2013","volume":"174","author":"Stepanova","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2010.08.026","article-title":"Manifestations of chronic hepatitis C virus infection beyond the liver","volume":"8","author":"Jacobson","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0035","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.02.042_b0040","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0045","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0050","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s10620-006-9708-x","article-title":"Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection","volume":"52","author":"Kallman","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.02.042_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1477-7525-10-92","article-title":"Review of patient-reported outcome measures in chronic hepatitis C","volume":"7","author":"Kleinman","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhep.2016.02.042_b0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)","volume":"60","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0065","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","article-title":"Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C","volume":"12","author":"Younossi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0070","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.21565","article-title":"The effects of HCV infection and management on health-related quality of life","volume":"45","author":"Younossi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0168-8278(00)00026-X","article-title":"The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity","volume":"34","author":"McHutchison","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0080","first-page":"371A","article-title":"Interferon (IFN), Ribavirin (RBV), duration of treatment and baseline Patient-Reported Outcomes (PROs) predict adherence to the new regimens for treatment of Chronic Hepatitis C (CH-C)","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","article-title":"Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.02.042_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2016.99","article-title":"An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens","author":"Younossi","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.02.042_b0095","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.042_b0105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0110","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0115","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.02.042_b0120","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0125","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0130","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jhep.2016.02.042_b0145","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","article-title":"Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C","volume":"12","author":"Younossi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0155","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/liv.12886","article-title":"The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study","volume":"36","author":"Younossi","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.02.042_b0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiv005","article-title":"Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes","volume":"212","author":"Younossi","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.042_b0175","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.042_b0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/apt.13269","article-title":"The patient\u2019s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life","volume":"42","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.02.042_b0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/apt.12354","article-title":"Health-related quality of life in genotype 1 treatment-na\u00efve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study","volume":"38","author":"Vera-Llonch","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.02.042_b0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jvh.12227","article-title":"Work productivity among treatment-na\u00efve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment","volume":"22","author":"Aggarwal","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.02.042_b0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","article-title":"Systematic review: patient-reported outcomes in chronic hepatitis C\u2013the impact of liver disease and new treatment regimens","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.02.042_b0200","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s11606-011-1655-3","article-title":"Determining whether a patient is feeling better: pitfalls from the science of human perception","volume":"26","author":"Redelmeier","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0205","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.042_b0210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1012588218728","article-title":"Interpreting SF-36 summary health measures: a response","volume":"10","author":"Ware","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2016.02.042_b0215","first-page":"604","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2016.02.042_b0220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.02.042_b0225","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2016.02.042_b0230","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2015.07.035","article-title":"Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection","volume":"14","author":"Gerber","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0235","doi-asserted-by":"crossref","first-page":"11974","DOI":"10.3748\/wjg.v21.i42.11974","article-title":"Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015","volume":"21","author":"Monaco","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.02.042_b0240","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2011.09.015","article-title":"Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition","volume":"56","author":"Byrnes","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.042_b0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1524-4733.2009.00585.x","article-title":"A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries","volume":"13","author":"Two","year":"2010","journal-title":"Value Health"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T10:59:48Z","timestamp":1536922788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816300083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0168827816300083"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.042","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}